The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.
暂无分享,去创建一个
[1] P. Ponka,et al. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. , 1979, Biochimica et biophysica acta.
[2] David Beach,et al. p21 is a universal inhibitor of cyclin kinases , 1993, Nature.
[3] M. Mahmoudi,et al. Comparison of two different hybridization systems in northern transfer analysis. , 1989, BioTechniques.
[4] D. Richardson. Potential of iron chelators as effective antiproliferative agents. , 1997, Canadian journal of physiology and pharmacology.
[5] S. Elledge,et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.
[6] S. Bi,et al. p53 in chronic myeloid leukemia cell lines. , 1992, Leukemia.
[7] A. Davidoff,et al. Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. , 1992, Oncogene.
[8] D. Becton,et al. Antileukemic effects of deferoxamine on human myeloid leukemia cell lines. , 1989, Cancer research.
[9] G. Kontoghiorghes,et al. Comparison of activity of deferoxamine with that of oral iron chelators against human neuroblastoma cell lines. , 1989, Cancer Research.
[10] H. Munro,et al. Cytoplasmic protein binds in vitro to a highly conserved sequence in the 5' untranslated region of ferritin heavy- and light-subunit mRNAs. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[11] D. Richardson,et al. The uptake of iron and transferrin by the human malignant melanoma cell. , 1990, Biochimica et biophysica acta.
[12] Barbara Neupert,et al. A specific mRNA binding factor regulates the iron-dependent stability of cytoplasmic transferrin receptor mRNA , 1989, Cell.
[13] R. Hider,et al. Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines. , 1992, Cancer research.
[14] L. V. van Grunsven,et al. The CDK inhibitor p21WAF1/Cip1 is induced through a p300-dependent mechanism during NGF-mediated neuronal differentiation of PC12 cells. , 1996, Oncogene.
[15] R. Klausner,et al. Cellular regulation of the iron-responsive element binding protein: disassembly of the cubane iron-sulfur cluster results in high-affinity RNA binding. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[16] P. Ponka,et al. Mobilization of iron from reticulocytes , 1979, FEBS letters.
[17] D. Richardson. Cytotoxic analogs of the iron(III) chelator pyridoxal isonicotinoyl hydrazone: effects of complexation with copper(II), gallium(III), and iron (III) on their antiproliferative activities , 1997, Antimicrobial agents and chemotherapy.
[18] D. Richardson,et al. Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease. , 1998, The Journal of laboratory and clinical medicine.
[19] M. Brechbiel,et al. Tumor cell cytotoxicity of a novel metal chelator. , 1998, Blood.
[20] C. Hershko,et al. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal. , 1981, The Journal of laboratory and clinical medicine.
[21] G. Stark,et al. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[22] G. Hefter,et al. Iron chelators of the pyridoxal isonicotinoyl hydrazone class Part II. Formation constants with iron(III) and iron(II) , 1990 .
[23] D. Richardson,et al. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. , 1997, Biochimica et biophysica acta.
[24] A. Levine,et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.
[25] M. Freedman,et al. Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. , 1984, Blood.
[26] L. Pickart,et al. Cytotoxic chelators and chelates 1. Inhibition of DNA synthesis in cultured rodent and human cells by aroylhydrazones and by a copper(II) complex of salicylaldehyde benzoyl hydrazone , 1982 .
[27] D. Givol,et al. Induction of WAF1/CIP1 by a p53-independent pathway. , 1994, Cancer research.
[28] D. Richardson,et al. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. , 1997, Blood.
[29] G. Mann,et al. Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. , 1993, The Journal of biological chemistry.
[30] W. El-Deiry,et al. Regulation of p21WAF1/CIP1 expression by p53-independent pathways. , 1996, Oncogene.
[31] J Lucas,et al. Neuroblastoma sensitivity to growth inhibition by deferrioxamine: evidence for a block in G1 phase of the cell cycle. , 1993, Cancer research.
[32] D. Lane,et al. What the papers say: The p53‐mdm2 autoregulatory feedback loop: A paradigm for the regulation of growth control by p53? , 1993 .
[33] B. Vogelstein,et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.
[34] K. Ganeshaguru,et al. Effect of Iron Deficiency and Desferrioxamine on DNA Synthesis in Human Cells , 1976, British journal of haematology.
[35] M. Hentze,et al. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[36] H. Varmus,et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.
[37] R. G. Hughes,et al. Antineoplastic and antiherpetic activity of spermidine catecholamide iron chelators. , 1984, Biochemical and biophysical research communications.
[38] A. Levine. p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.
[39] D. Richardson,et al. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. , 1995, Blood.
[40] A. Gräslund,et al. Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: possible regulation mechanism. , 1983, Biochemical and biophysical research communications.
[41] A. Donfrancesco,et al. Deferoxamine, Cyclophosphamide, Etoposide, Carboplatin, and Thiotepa (D‐CECaT): A New Cytoreductive Chelation‐Chemotherapy Regimen in Patients with Advanced Neuroblastoma , 1992, American journal of clinical oncology.
[42] G. Wahl,et al. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. , 1996, Genes & development.
[43] J. Trent,et al. WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.
[44] D. Becton,et al. Deferoxamine inhibition of human neuroblastoma viability and proliferation. , 1988, Cancer research.
[45] N. Gray,et al. Modulation of the RNA-binding activity of a regulatory protein by iron in vitro: switching between enzymatic and genetic function? , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[46] A. Donfrancesco,et al. Effects of a single course of deferoxamine in neuroblastoma patients. , 1990, Cancer research.
[47] C. Chitambar,et al. Effect of hydroxyurea on cellular iron metabolism in human leukemic CCRF-CEM cells: changes in iron uptake and the regulation of transferrin receptor and ferritin gene expression following inhibition of DNA synthesis. , 1995, Cancer research.
[48] Z. Estrov,et al. In vitro and in vivo effects of deferoxamine in neonatal acute leukemia , 1987 .
[49] P. Reichard,et al. Reduction of ribonucleotides. , 1979, Annual review of biochemistry.
[50] J. Blatt,et al. Mechanism of antineuroblastoma activity of deferoxamine in vitro. , 1988, The Journal of laboratory and clinical medicine.
[51] U. Moll,et al. Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage , 1996, Molecular and cellular biology.
[52] W. El-Deiry,et al. AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression , 1997, Nature Genetics.
[53] X. H. Wang,et al. In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. , 1987, Blood.
[54] U. Gullberg,et al. Involvement of the tumor suppressor gene p53 in tumor necrosis factor-induced differentiation of the leukemic cell line K562. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[55] R. Klausner,et al. cis-trans models for post-transcriptional gene regulation. , 1989, Science.
[56] J. Domenico,et al. Effects of agents that inhibit cellular iron incorporation on bladder cancer cell proliferation. , 1993, Blood.
[57] M. Hentze,et al. Nitric oxide and oxidative stress (H2O2) control mammalian iron metabolism by different pathways , 1996, Molecular and cellular biology.